Regimens for Cirrhotic Patients

Paul Y. Kwo

Research output: Contribution to journalArticle


Therapy for hepatitis C has entered the era of all-oral direct-acting antiviral agents. Sustained response rates are now greater than 90% for all genotypes, although patients with cirrhosis remain the most difficult to treat. There are limited data for patients with cirrhosis and with hepatitis C genotypes 4 and 6 with cirrhosis. Genotype 3 patients with cirrhosis need additional strategies to achieve the sustained virologic response rates seen in genotype 1 patients with cirrhosis. This article outlines the currently available therapies for patients with cirrhosis and hepatitis C across all genotypes, with suggested management strategies.

Original languageEnglish (US)
Pages (from-to)657-667
Number of pages11
JournalClinics in Liver Disease
Issue number4
StatePublished - Nov 1 2015


  • Cirrhosis
  • Direct-acting antivirals
  • Hepatitis C
  • Ledipasvir
  • Ombitasvir
  • Paritaprevir
  • Simeprevir
  • Sofosbuvir

ASJC Scopus subject areas

  • Hepatology

Fingerprint Dive into the research topics of 'Regimens for Cirrhotic Patients'. Together they form a unique fingerprint.

  • Cite this